PENNANT/ DESCENDING TRIANGLE ON CTXR. WITH CATALYST AHEAD OF PHASE 3 DATA FOR CATHETER RELATED BLOOD STREAM INFECTION 2H 2020 NASDAQ:CTXR , SHOULD SEE A BREAKOUT FOR A NICE RUN
Hello,
What is CTXR?
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous...
CTXR has shown a nice breakout with heavy volume, followed by a pullback to the crime scene on low volume while RSI hovering just around 50, it is now moving above the 50 MA and breaking out of the second downtrendline, a good risk/reward setup
Citius Pharmaceuticals, Inc. engages in the development and commercialization of therapeutic products. It offers Mino-Lok, a patented solution to treat and salvage infected central venous catheters in patients with catheter related bloodstream infections and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for treatment of...
Citius recently Announced Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
Top line data due for 1H 2020
insider Own 42.50%
Shs Float 16.64M
Market Cap 28.70M
Increase in hedge fund holdings
